BioSpace News Archive

Gilsbar is excited to announce a first ever partnership for both their employees and Gilsbar employer groups that provides access to non-surgical orthopedic alternatives

Existing investors also participated in the round to further Magenta’s development of miniaturized pumps to treat heart failure patients

Axonics Modulation Technologies, Inc. a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, announced the results from its ARTISAN-SNM study were published online in the peer-reviewed Journal of Urology.

The first quarter results press release will be issued on August 14, 2019 before the conference call.

Mylan N.V. announced its financial results for the three and six months ended June 30, 2019.

Opinion Granted Based on Significant Overall Survival Benefit for KEYTRUDA in Combination with Axitinib Compared to Sunitinib in Phase 3 KEYNOTE-426 Trial

Mylan’s Board of Directors shared the following statement regarding Heather Bresch’s retirement, which will be effective upon the closing of the combination of Mylan and Upjohn, a division of Pfizer.

Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company.

Combines Mylan’s sustainable, diverse and differentiated portfolio of medicines with Upjohn’s trusted, iconic brands

Company to hold second quarter 2019 conference call on August 8